September 14, 2026 05:30 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
India-UAE Comprehensive Strategic Partnership in focus: Modi meets Abu Dhabi Crown Prince on BRICS sidelines | Xi Jinping lands in India for BRICS; big Modi meeting set for New Delhi | ‘Hospitality on another level’: South African official stunned by India’s BRICS hosting | Suvendu Adhikari eats fish bhog at Kalighat Temple amid Bageshwar Baba row | Bangladeshi Hindu monk Chinmoy Krishna Das breaks down emotionally as he gets 5-hour parole to attend mother’s funeral | Sheikh Hasina’s daughter Saima Wazed quits WHO post amid fraud allegations | After days of silence, China confirms Xi Jinping’s India visit for BRICS Summit | Big setback for Abhishek Banerjee as CID arrests aide Sumit Roy | Firebrand Tukaram Mundhe’s Food Safety Blitz Hits ISKCON Juhu, 3 Licences Suspended | Vande Mataram row erupts in INDIA bloc: Congress objects, ally NC hits back, BJP pounces
Coronavirus Vaccine

Adar Poonawalla thanks PM Modi for decisive 'policy changes and swift financial aid' amid vaccine shortage

| @indiablooms | Apr 21, 2021, at 07:18 am

Mumbai/IBNS: Serum Institute of India (SII) CEO Adar Poonawalla has lauded the Centre's policy change in vaccination, bringing all above 18 under the mass drive and extending financial support to the vaccine manufacturers.

SII which is manufacturing Covishied, developed by Oxford University and Swedish drug giant AstraZeneca, in India has been given Rs 3,000 crore as 100 per cent advance till July, reported NDTV citing senior sources in the Finance Ministry.

A similar advance of Rs 1,500 crore has been given to Hyderabad-based Bharat Biotech, the producer of indegenous Covaxin, the report added.

"This will ensure that the two companies get necessary funding to continue and scale up production," the sources said, the report added.

Earlier, Adar Poonawalla had appealed to the Centre for funds to scale up manufacturing amid high demand of the vaccine within and outside India.

Both Bharat Biotech and SII were facing shortage of funds "to scale up production, purchase raw materials, pay staff, and make and distribute enough doses of the vaccines", stated the report.

Poonawall, on Tuesday, tweeted in appreciation of the Centre's move.

The states can now buy coronavirus vaccine doses directly from manufacturers in the "liberalised and accelerated Phase 3 strategy of COVID-19 vaccination".

.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.